Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05154994 |
| Title | Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma (RESOLVE) |
| Acronym | RESOLVE |
| Recruitment | Suspended |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | University of Utah |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |